0.8699
price up icon0.57%   0.0049
after-market Dopo l'orario di chiusura: .85 -0.0199 -2.29%
loading
Precedente Chiudi:
$0.865
Aprire:
$0.86
Volume 24 ore:
166.55K
Relative Volume:
0.06
Capitalizzazione di mercato:
$5.76M
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00104
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
-5.55%
1M Prestazione:
-19.45%
6M Prestazione:
-78.52%
1 anno Prestazione:
-96.11%
Intervallo 1D:
Value
$0.845
$0.87
Intervallo di 1 settimana:
Value
$0.8308
$0.97
Portata 52W:
Value
$0.7846
$41.50

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
Nome
Biodexa Pharmaceuticals Plc Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
13
Name
Cinguettio
Name
Prossima data di guadagno
2024-06-13
Name
Ultimi documenti SEC
Name
BDRX's Discussions on Twitter

Confronta BDRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
0.8699 5.76M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-08 Iniziato Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie

pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Jan 30, 2025

Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 03, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN

Jan 03, 2025
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN

Dec 29, 2024
pulisher
Nov 22, 2024

Result of General Meeting - GlobeNewswire

Nov 22, 2024
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewswire

Oct 15, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com

Oct 04, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - Yahoo Finance

Sep 19, 2024
pulisher
Jul 17, 2024

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Jul 17, 2024
pulisher
Mar 01, 2024

PRFX Stock Quote Price and Forecast - CNN

Mar 01, 2024
pulisher
Feb 09, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 09, 2024
pulisher
Dec 19, 2023

Why Biodexa Pharmaceuticals (BDRX) Shares Are Getting Hammered - TradingView

Dec 19, 2023
pulisher
Jul 05, 2023

Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune

Jul 05, 2023
pulisher
Jun 27, 2023

Biodexa Pharma (BDRX) Stock Rallied 27% on Investor Interest - AskTraders.com

Jun 27, 2023
pulisher
Jun 23, 2023

Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com

Jun 23, 2023
pulisher
Mar 30, 2023

Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis - MarketBeat

Mar 30, 2023
pulisher
Mar 30, 2023

BDRX News Today | Why did Biodexa Pharmaceuticals stock go down today? - MarketBeat

Mar 30, 2023
pulisher
Mar 28, 2023

Midatech PharmaDevelopment pipeline expands with MTD217 - research-tree.com

Mar 28, 2023

Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):